<DOC>
	<DOCNO>NCT03026517</DOCNO>
	<brief_summary>The purpose study test whether safe give phenformin standard drug combination dabrafenib + trametinib . The combination dabrafenib plus trametinib standard treatment patient metastatic melanoma whose melanoma mutation gene call BRAF .</brief_summary>
	<brief_title>Clinical Trial Phenformin Combination With Dabrafenib Trametinib Patients With BRAF-mutated Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<mesh_term>Phenformin</mesh_term>
	<criteria>AJCC ( 2009 ) stage IV melanoma , stage III melanoma curable surgery progressing . Patients must least 1 target lesion measurable RECIST 1.1 criterion . The melanoma must harbor activate BRAF V600 mutation . Prior therapy BRAF and/or MEK inhibitor allow doseescalation phase . However , patient discontinue previous RAF inhibitor due intolerance drug rather due progression eligible . Histologic proof melanoma review confirm treat institution . The melanoma must document BRAFV600E BRAFV600K mutation genotyping IHC12 perform CLIA certify laboratory . At MSK , Diagnostic Molecular Pathology laboratory develop implement target capturebased nextgeneration DNA sequence assay , MSKIMPACTTM , profile proteincoding exon select intron 410 oncogene tumor suppressor gene formalinfixed paraffin embed tissue ( Cheng , D.T. , et al. , J Mol Diagn , 2015 . 17 ( 3 ) : p. 25164 ) . MSKIMPACTTM approve NY State Department Health run clinical assay CLIAcompliant Diagnostic Molecular Pathology laboratory . MSKIMPACTTM capable detecting mutation , copy number alteration , structural variation . BRAF Exon15 capture MSKIMPACTTM panel c.1799T &gt; A ( p.V600E ) mutation fully validate per NYS requirement . Detailed result validation mutation include validation package submit NY State Department Health . At MGH , sample test use multiplex polymerase chain reaction ( PCR ) technology call Anchored Multiplex PCR ( AMP ) single nucleotide variant ( SNV ) insertion/deletion ( indel ) detection genomic DNA use next generation sequencing ( NGS ) . Briefly , genomic DNA isolate formalinfixed paraffin embed tumor specimen shear Covaris M220 instrument , follow endrepair , adenylation , ligation adapter . A sequencing library target hotspots exon 39 gene ( include BRAF , exons 11 15 ) generate use two heminested PCR reaction . Illumina MiSeq 2 x 147 base pairedend sequence result align hg19 human genome reference use BWAMEM ( Li H Durbin R. Bioinformatics 2009 ; 25 ( 14 ) :175460 ) . MuTect ( Cibulskis K , et al . Nat Biotechnol 2013 ; 31 ( 3 ) :2139 ) laboratorydeveloped insertion/deletion analysis algorithm use SNV indel variant detection , respectively . This assay validate detect SNV indel variant 5 % allelic frequency high target region sufficient read coverage . This test develop , performance characteristic determine MGH Center Integrated Diagnostics . Patients must adequately recover surgery , radiation therapy , surgical complication prior enrollment . Age ≥ 18 year old . ECOG performance status 02 . The ability swallow pill otherwise follow protocol . Patients treat CNS metastasis eligible symptomatic CNS disease stable least 6 week patient require ≤ equivalent 2 mg/day dexamethasone . Patients must adequate organ marrow function define : Absolute neutrophil count ≥1.5 K/mcL Platelets ≥100 K/mcL Hemoglobin ≥ 9.0 g/dL Total bilirubin ≤ 1.2 X institutional upper limit normal ( ULN ) ≤ 3.0 X institutional ULN patient Gilbert 's Syndrome AST ( SGOT ) ALT ( SGPT ) ≤ 1.2 X institutional ULN Creatinine ≤ 1.4 mg/dl Hgb A1c ≤ 5.7 % , 5.86.5 % normal fast glucose Type 1 Type II diabetes , Hgb A1c &gt; 6.5 % . A history renal failure ( unless recover least 6 month ) , lactic acidosis , recurrent severe hypoglycemia , significant chronic obstructive lung disease . Patients exclude reversible episode elevate creatinine due hypovolemia . Acute chronic liver renal disease . Concurrent use hypoglycemic agent systemic therapy melanoma . Palliative limitedfield radiation therapy allow Current use prohibit medication dabrafenib/trametinib Presence condition interfere significantly absorption drug . A history know glucose6phosphate dehydrogenase ( G6PD ) deficiency . Pregnant woman lactate woman A prior concurrent metastatic second malignancy within 3 year , even require active therapy . For example , patient concomitant indolent Bcell malignancy eligible . Patients prior resect insitu stage I malignancy felt cure eligible . Other uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . New York Heart Association class ≥2 exclusion criterion . QTc interval &gt; 500 msec , unless bundle branch block also present . Patients brain metastasis unless meet criterion section 6.1.8 . In dose expansion phase trial , prior treatment BRAF inhibitor exclusion criterion . Inclusion Women Minorities : Both men woman , member race ethnic group eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Phenformin</keyword>
	<keyword>Dabrafenib</keyword>
	<keyword>Trametinib</keyword>
	<keyword>BRAF</keyword>
	<keyword>15-318</keyword>
</DOC>